RedHill Biopharma Ltd.
RDHL
$1.64
-$0.09-5.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 157.62% | 108.60% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 157.62% | 108.60% | -- | -- | -- |
| Cost of Revenue | 38.85% | 29.21% | -- | -- | -- |
| Gross Profit | 387.72% | 229.92% | -- | -- | -- |
| SG&A Expenses | -40.63% | -43.04% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.70% | -23.60% | -- | -- | -- |
| Operating Income | 60.05% | 50.57% | -- | -- | -- |
| Income Before Tax | 69.14% | 68.46% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.14% | 68.46% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.14% | 68.46% | -- | -- | -- |
| EBIT | 60.05% | 50.57% | -- | -- | -- |
| EBITDA | 59.48% | 48.63% | -- | -- | -- |
| EPS Basic | 91.23% | 89.99% | -- | -- | -- |
| Normalized Basic EPS | 93.43% | 97.91% | -- | -- | -- |
| EPS Diluted | 91.23% | 89.99% | -- | -- | -- |
| Normalized Diluted EPS | 93.43% | 97.91% | -- | -- | -- |
| Average Basic Shares Outstanding | 97.35% | 166.50% | -- | -- | -- |
| Average Diluted Shares Outstanding | 100.00% | 300.00% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |